N/A
Manufactured by GlaxoSmithKline LLC
20,040 FDA adverse event reports analyzed
Last updated: 2026-05-19
Advair is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by GlaxoSmithKline LLC. The most commonly reported adverse reactions for Advair include DYSPNOEA, PNEUMONIA, DRUG INEFFECTIVE, ASTHMA, COUGH. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for Advair.
Out of 8,891 classified reports for Advair:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 20,040 FDA FAERS reports that mention Advair. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DYSPNOEA, PNEUMONIA, DRUG INEFFECTIVE, ASTHMA, COUGH, PRODUCT QUALITY ISSUE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list GlaxoSmithKline LLC in connection with Advair. Always verify the specific product and NDC with your pharmacist.
Explore other medications manufactured by GlaxoSmithKline LLC and compare their safety profiles:
The following drugs share commonly reported adverse reactions with Advair: